|Bid||74.31 x 200|
|Ask||74.90 x 100|
|Day's Range||74.07 - 76.47|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.46|
|Forward Dividend & Yield||2.08 (2.73%)|
|1y Target Est||N/A|
U.S. stock futures are trending higher this morning, as Wall Street continues to digest the Federal Reserve’s interest rate hike and accompanying policy statement. Diving right into Wednesday’s options activity, JD.com Inc(ADR) (NASDAQ:JD) attracted a spike in call volume after Stifel resumed coverage on the Chinese e-retailer. Meanwhile, Time Warner Inc. (NYSE:TWX) was also call heavy despite an ongoing lawsuit with the government over AT&T Inc.’s (NYSE:T) acquisition.
Two months after Gilead Sciences Inc.’s breakthrough treatment was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, ...
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Shares of Gilead Sciences (GILD) are down today, a day after rising on the company's upbeat data on its developing cancer therapy. Today, Kite, which Gilead bought earlier this year, announced updated results from the ongoing study of KTE-C19, part of its CAR-T therapy lineup aimed at patients with relapsed or refractory acute lymphoblastic leukemia. Kite said that with a minimum of eight weeks of follow-up, 71% of patients achieved complete tumor remission or complete remission with incomplete hematological recovery.
Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.
More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.
Launched little more than a year ago to produce cancer-fighting cell therapies just outside a tumor cell's door, an Emeryville company will be bought by biotech powerhouse Gilead Sciences Inc. for up to $567 million. The technologies behind Cell Design Labs Inc. — born out of the work of University of California, San Francisco, Professor Wendell Lim — could boost the effectiveness of so-called CAR-T drugs while decreasing the risk of potential side effects from those groundbreaking treatments. The buyout is structured with Cell Design Labs getting about $175 million upfront and up to $322 million paid out to most of the company's shareholders after hitting undisclosed milestones.
Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...